BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 2871172)

  • 1. Pharmacology of ORF 17578, a new histamine H2-receptor antagonist: comparison with cimetidine and ranitidine.
    Katz LB; Scott CK; Shriver DA
    J Pharmacol Exp Ther; 1986 May; 237(2):404-10. PubMed ID: 2871172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological comparison of ORF 17910, a potent, long-acting histamine H2-receptor antagonist, to cimetidine and ranitidine.
    Katz LB; Scott CK; Shriver DA
    J Pharmacol Exp Ther; 1986 Aug; 238(2):587-93. PubMed ID: 2874214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ORF 17583, other histamine H2-receptor antagonists and omeprazole on gastric acid secretory states in rats and dogs.
    Katz LB; Tobia AJ; Shriver DA
    J Pharmacol Exp Ther; 1987 Aug; 242(2):437-42. PubMed ID: 2886642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of some of the pharmacological properties of etintidine, a new histamine H2-receptor antagonist, with those of cimetidine, ranitidine and tiotidine.
    Cavanagh RL; Usakewicz JJ; Buyniski JP
    J Pharmacol Exp Ther; 1983 Jan; 224(1):171-9. PubMed ID: 6129316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of etintidine, a new histamine H2-receptor antagonist.
    Scott CK; Katz LB; Shriver DA
    Arch Int Pharmacodyn Ther; 1986 May; 281(1):5-21. PubMed ID: 2875695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of mifentidine, a novel H2-receptor antagonist.
    Pagani F; Micheletti R; Brambilla A; Schiavone A; Montagna E; Ciprandi C; Giachetti A
    Arzneimittelforschung; 1985; 35(1A):451-5. PubMed ID: 2859036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the H2 receptor antagonist and gastric acid antisecretory properties of Wy-45,727.
    Nielsen ST
    J Pharmacol Exp Ther; 1987 Aug; 242(2):607-13. PubMed ID: 2886646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo and in vitro effects of CM 57755, a new gastric antisecretory agent acting on histamine H2 receptors.
    Lavezzo A; Manzoni L; Aureggi G; Nisato D; Bianchetti A; Carminati P
    Int J Tissue React; 1984; 6(2):155-65. PubMed ID: 6145676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of gastric acid secretion by H2-receptor antagonists.
    Nielsen ST
    Arch Int Pharmacodyn Ther; 1986 Jul; 282(1):151-60. PubMed ID: 2876686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the animal pharmacology of ranitidine--a new, selective histamine H2-antagonist.
    Brittain RT; Daly MJ
    Scand J Gastroenterol Suppl; 1981 Jun; 69():1-9. PubMed ID: 6119770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisecretory and antiulcer activities of a potent new histamine H2-receptor antagonist with an intermediate duration of action.
    Borella L; Russell J; Rimele TJ; Grimes D; Failli A; Mir GN
    Arzneimittelforschung; 1988 Mar; 38(3):366-72. PubMed ID: 2898247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of the gastric antisecretory activity of histamine H2-receptor antagonists by clebopride.
    Fernández AG; Massingham R; Roberts DJ
    Methods Find Exp Clin Pharmacol; 1988 May; 10(5):285-93. PubMed ID: 2899659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on MK-208 (YM-11170) a new, slowly dissociable H2-receptor antagonist.
    Pendleton RG; Torchiana ML; Chung C; Cook P; Wiese S; Clineschmidt BV
    Arch Int Pharmacodyn Ther; 1983 Nov; 266(1):4-16. PubMed ID: 6141772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
    Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea.
    Sekiguchi H; Hamada K; Kobayashi F; Taga F; Uchida H
    Arzneimittelforschung; 1993 Feb; 43(2):129-33. PubMed ID: 8096132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective gastric antilesion properties of rioprostil, a prostaglandin E1 analog, in rats and dogs.
    Katz LB; Shriver DA; Tobia AJ; Rosenthale ME
    J Pharmacol Exp Ther; 1987 Sep; 242(3):927-33. PubMed ID: 3116199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a new potent H2-blocker, 3-]]]2-[(diaminomethylene)amino]-4-thiazolyl]methyl]-thio]-N2-sulfamoylpropionamidine (YM-11170) on gastric secretion induced by histamine and food in conscious dogs.
    Takagi T; Takeda M; Maeno H
    Arch Int Pharmacodyn Ther; 1982 Mar; 256(1):49-58. PubMed ID: 6124219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs.
    Lin TM; Evans DC; Warrick MW; Pioch RP
    J Pharmacol Exp Ther; 1986 Nov; 239(2):406-10. PubMed ID: 2877081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisecretory effects of two new histamine H2-receptor antagonists.
    Bickel M; Herling AW; Rising TJ; Wirth K
    Arzneimittelforschung; 1986 Sep; 36(9):1358-63. PubMed ID: 2878669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the new H2-receptor antagonist mifentidine on gastric acid secretion in the cat: comparison with cimetidine and ranitidine.
    Scarpignato C; Tramacere R; Tangwa M; Bertaccini G
    Arch Int Pharmacodyn Ther; 1985 Jul; 276(1):142-51. PubMed ID: 2864903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.